```html

Quiescent Hypophysitis – A Complete Patient‑Friendly Guide

Overview

Quiescent hypophysitis is a rare, chronic inflammatory disorder of the pituitary gland in which the inflammation has largely resolved (hence “quiescent”), leaving behind pituitary tissue that may be scarred or partially dysfunctional. The condition can emerge after an acute episode of hypophysitis, after treatment for a pituitary tumour, or as an isolated, slowly progressive process.

• Who it affects: Most cases are reported in adults aged 30‑60 years, with a slight female predominance (≈55‑60%). However, it can occur at any age, including in children and the elderly.
• Prevalence: Exact prevalence is unknown because many patients remain asymptomatic. Epidemiologic studies suggest that hypophysitis (all forms) accounts for 0.5‑1.5 % of all pituitary disorders, and the quiescent subset represents roughly 10‑20 % of those cases.<sup>[1] Mayo Clinic</sup>
• Why it matters: Even when inflammation is inactive, residual pituitary damage can cause hormone deficiencies, visual disturbances, or mass‑effect symptoms that require lifelong monitoring.

Symptoms

Symptoms arise from two main mechanisms: (1) residual pituitary hormone deficiency and (2) mass effect from scar tissue or a residual lesion.

Hormonal deficiency symptoms

• Adrenal insufficiency (ACTH deficiency): Fatigue, weakness, loss of appetite, low blood pressure, nausea, salt craving.
• Hypothyroidism (TSH deficiency): Cold intolerance, weight gain, constipation, dry skin, hair loss.
• Gonadal dysfunction (LH/FSH deficiency): Decreased libido, menstrual irregularities or amenorrhea in women, erectile dysfunction in men, infertility.
• Growth hormone deficiency: Decreased muscle mass, increased abdominal fat, poor quality of life, reduced bone density.
• Prolactin abnormalities: May cause galactorrhea or, less commonly, low prolactin leading to poor lactation.

Mass‑effect / local symptoms

• Headache: Persistent, often dull, localized to the frontal or retro‑orbital region.
• Visual field defects: Bitemporal hemianopsia or peripheral vision loss if the optic chiasm is compressed.
• Diplopia (double vision): Resulting from involvement of cranial nerves III, IV, or VI.
• Persistent nausea or vomiting: Due to raised intracranial pressure.
• Feeling of fullness in the head: Described as “pressure” behind the eyes.

Systemic/non‑specific signs

• Weight loss or gain (depending on hormonal axis affected)
• Unexplained depression or mood changes
• Reduced exercise tolerance

Causes and Risk Factors

Quiescent hypophysitis is not a single disease entity but a stage of several underlying processes. The most common pathways include:

Autoimmune hypophysitis

• Autoantibodies target pituitary cells (e.g., anti‑pituitary antibodies, anti‑GAD65).
• Often associated with other autoimmune disorders such as Hashimoto thyroiditis, type 1 diabetes, or lupus.<sup>[2] NIH</sup>

Secondary to treatment

• Radiation therapy for pituitary adenomas or head‑and‑neck malignancies can trigger chronic inflammation.
• Immune checkpoint inhibitors (e.g., ipilimumab, nivolumab) used in cancer therapy may cause an acute hypophysitis that later becomes quiescent.

Infectious or granulomatous causes

• Tuberculosis, sarcoidosis, syphilis, or fungal infections can initiate an inflammatory reaction that later heals with fibrosis.

Pregnancy‑related (lymphocytic) hypophysitis

• Often presents in the third trimester or early postpartum; many women transition to a quiescent state after delivery.

Risk factors

• Female sex (especially during or after pregnancy)
• Personal or family history of autoimmune disease
• Previous pituitary surgery or radiation
• Use of immune‑modulating cancer therapies
• Genetic susceptibility (HLA‑DR4, HLA‑DQ8 have been implicated)

Diagnosis

Because symptoms can mimic other pituitary disorders, a systematic approach is essential.

Clinical assessment

• Detailed history of prior pituitary disease, pregnancy, cancer treatment, or autoimmune conditions.
• Physical exam focusing on visual fields, cranial nerve function, and signs of hormone deficiency.

Laboratory testing

• Baseline pituitary panel: Morning cortisol, ACTH, free T4, TSH, LH, FSH, estradiol/testosterone, prolactin, IGF‑1 (growth‑hormone surrogate).
• Dynamic tests if needed (e.g., ACTH stimulation, insulin‑tolerance test).
• Autoantibody screening (anti‑pituitary, anti‑thyroid peroxidase) when autoimmune etiology is suspected.

Imaging

• MRI of the sellar region is the gold standard. Typical findings in quiescent hypophysitis include:
  • Intermediate‑to‑low T1 signal and a thickened, non‑enhancing pituitary stalk.
  • Reduced gland size compared with prior scans.
  • Absence of active gadolinium enhancement (indicating quiescence).
• CT is rarely used but can help rule out bony involvement.

Other investigations

• Visual‑field testing (automated perimetry) if visual symptoms are present.
• Lumbar puncture only if infectious or granulomatous disease is strongly suspected.

Diagnostic criteria (proposed)

1. History of prior hypophysitis or risk factor exposure.
2. MRI evidence of a pituitary lesion with no active enhancement.
3. Documented ≥1 pituitary hormone deficiency.
4. Exclusion of alternative causes (tumor, infection, metastasis).

Treatment Options

Treatment aims to (1) replace deficient hormones, (2) manage residual mass effect, and (3) prevent further inflammation if activity recurs.

Hormone replacement therapy (HRT)

• Cortisol deficiency: Hydrocortisone 15‑20 mg/day in divided doses or equivalent (e.g., prednisone 5 mg). Stress dosing during illness or surgery is critical.
• Thyroid deficiency: Levothyroxine 1.6 µg/kg/day, titrated to normalize TSH (0.4‑4.0 mIU/L). Start only after adequate cortisol coverage.
• Gonadal axis:
  • Women: Estrogen‑progestin therapy or transdermal estradiol; consider fertility counseling.
  • Men: Testosterone gel or injections, dose adjusted to maintain serum testosterone 300‑1000 ng/dL.
• Growth hormone: Recombinant GH (somatropin) for adults with proven GH deficiency, after other deficiencies are corrected. Dose titrated to IGF‑1 within age‑adjusted range.
• Prolactin: Usually not replaced; dopamine agonists (e.g., cabergoline) are used only if hyperprolactinemia causes symptoms.

Management of residual mass effect

• Observation: Most quiescent lesions remain stable; serial MRI every 6‑12 months is recommended.
• Surgical decompression: Indicated if vision deteriorates or tumor‑like growth is evident. Endoscopic trans‑sphenoidal surgery is the preferred approach.
• Radiation therapy: Stereotactic radiosurgery (Gamma Knife) may be considered for refractory mass effect, but carries a risk of worsening hypopituitarism.

Anti‑inflammatory strategies (if re‑activation occurs)

• High‑dose glucocorticoids (prednisone 1 mg/kg/day taper) for acute flare‑ups.
• Immunosuppressants (azathioprine, methotrexate) have limited evidence; considered only in recurrent autoimmune cases.

Lifestyle and supportive measures

• Stress‑dose steroids education (carrying steroid emergency card and injectable hydrocortisone).
• Balanced diet with adequate calcium and vitamin D (especially if on glucocorticoids).
• Regular exercise tailored to energy levels; resistance training helps mitigate GH‑deficiency effects.
• Vaccinations: annual flu, COVID‑19, and pneumococcal vaccines, particularly for patients on chronic steroids.

Living with Quiescent Hypophysitis

Daily Management Tips

• Medication routine: Take steroids and thyroid medication on an empty stomach, at the same time each day.
• Symptom diary: Record fatigue, headache, visual changes, or signs of adrenal crisis (dizziness, nausea) to discuss with your endocrinologist.
• Medical alert ID: Wear a bracelet indicating “Adrenal Insufficiency – Requires Steroids”.
• Regular labs: Check cortisol, thyroid function, sex hormones, and IGF‑1 at least annually, or more often after medication changes.
• Vision screening: Yearly automated perimetry even if you feel fine; early detection of field loss can prevent permanent damage.
• Psychological support: Hormone deficits can affect mood; consider counseling or support groups.

Work and travel

• Plan for extra medication (double the supply) when traveling across time zones.
• Carry oral and injectable steroids in original packaging for customs.
• Inform employers of your condition if accommodations (e.g., break for medication) are needed.

Prevention

Because many cases stem from unavoidable triggers (e.g., pregnancy, cancer therapy), primary prevention is limited. However, the following measures can reduce the risk of secondary damage or flare‑ups:

• Prompt treatment of acute hypophysitis (e.g., with steroids) to limit permanent scarring.
• Careful dosing and tapering of glucocorticoids when used for other reasons.
• Regular monitoring during immune‑checkpoint inhibitor therapy; early endocrinology referral if hormone abnormalities appear.
• Vaccination against infections that can cause granulomatous pituitary disease (e.g., TB screening before immunosuppression).
• Maintain a healthy immune system—balanced diet, adequate sleep, stress reduction.

Complications

If left untreated or inadequately managed, quiescent hypophysitis can lead to:

• Adrenal crisis: Life‑threatening hypotension, shock, hypoglycemia. Mortality can exceed 30 % without rapid treatment.<sup>[3] CDC</sup>
• Progressive hormone deficiencies: Permanent loss of thyroid, gonadal, or growth‑hormone axes, affecting metabolism, fertility, bone health.
• Visual loss: Irreversible optic‑nerve damage if compression is not relieved.
• Osteoporosis: Due to combined effects of cortisol excess (if over‑treated), low estrogen/testosterone, and GH deficiency.
• Reduced quality of life: Fatigue, depression, and cognitive slowing are common when multiple axes are affected.
• Secondary tumor development: Rarely, chronic inflammation can predispose to pituitary adenoma formation.

When to Seek Emergency Care

References

1. Mayo Clinic. “Hypophysitis.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/hypophysitis
2. National Institutes of Health (NIH). “Autoimmune Hypophysitis.” 2022. https://www.nhlbi.nih.gov/health/autoimmune-hypophysitis
3. Centers for Disease Control and Prevention (CDC). “Adrenal Insufficiency and Crisis.” 2021. https://www.cdc.gov/endocrine/adrenal-insufficiency
4. Cleveland Clinic. “Pituitary Tumor (Hypophysitis) – Diagnosis and Treatment.” 2023. https://my.clevelandclinic.org/health/diseases/14770-pituitary-tumor
5. World Health Organization (WHO). “Guidelines for the Management of Pituitary Disorders.” 2022. https://www.who.int/publications/i/item/9789240026460

```